Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n = 534) or malignant (n = 831) breast diseases. Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy. Three hundred forty-nine patients were monitored during post-surgical follow-up for either a minimum of 5 years or until time of recurrence. Twenty-one patients with metastases were also monitored during chemotherapy. Elevated CA 15-3 and TPS levels were found in 28.6% and 30.0% of patients. CA 15-3 and TPS sensitivities rose to 71.9% and 66.3% in metastatic patients, respectively. The addition of TPS to CA 15-3 increased the sensitivity up to 44.4% in the overall population, and to 87.6% in patients with metastases. During post-surgical follow-up CA 15-3 was elevated in 65.7% and TPS in 61.3% of patients with recurrence. The combination of TPS and CA 15-3 increased the overall sensitivity by 12.7%. Longitudinal monitoring of metastatic patients undergoing chemotherapy demonstrated that, when positive, both CA 15-3 and TPS paralleled response to treatment. TPS monitoring may provide additional value when used in combination with CA15-3 during post-surgical follow-up of breast cancer patients.
D'Alessandro
R
R
Laboratory of Clinical Pathology, Regina Elena Cancer Institute, University of Rome Tor Vergata, Italy.
Roselli
M
M
Ferroni
P
P
Mariotti
S
S
Spila
A
A
Aloe
S
S
Carone
M D
MD
Abbolito
M R
MR
Carlini
S
S
Perri
P
P
Ricciotti
A
A
Botti
C
C
Conti
F
F
Vici
P
P
Chiappetta
N R
NR
Cognetti
F
F
Buonomo
O
O
Guadagni
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000556:secondary / Q000628:therapy; D018275:Carcinoma, Lobular / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000556:secondary / Q000628:therapy; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005260:Female; D005348:Fibrocystic Breast Disease / Q000097:blood; D006801:Humans; D007558:Italy; D008137:Longitudinal Studies; D008408:Mastectomy; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D010455:Peptides / Q000097:blood*; D011184:Postoperative Period; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D018396:Mucin-1; D010455:Peptides; C089984:tissue polypeptide specific antigen